Navigation Links
International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined significance (MGUS). The event is being cochaired by James R. Berenson, MD, who is Medical and Scientific Director at the IMBCR and Robert A. Kyle, MD, who is Professor of Medicine at the Mayo Clinic.

The goal of this roundtable discussion is to develop a consensus statement to be published in a major medical journal related to all aspects regarding the evaluation, follow-up and treatment of patients at risk for MGUS and its associated bone loss and fracture.

Topics for discussion include: addressing important issues such as which patients should be screened and how often; specific types of work-ups for patients; diagnostic testing for evaluation of bone disease; treatment measures for patients with significant bone loss and fractures; and other potential studies to be conducted for this disease population.

The event will take place February 25th at the Marriott Wardman Park Hotel just prior to the 12th Annual International Myeloma Workshop in Washington, D.C.

MGUS is a common condition in which a monoclonal paraprotein is detected in the blood and/or urine but these patients do not have a malignant disorder associated with the presence of this protein. More than 3% of individuals over 50 years of age and 5% of individuals over 70 have this condition. Studies show these individuals have an increased risk to develop cancers including myeloma and lymphoma with a very high risk of bone loss and fractures. There is no current consensus on the work-up, follow-up and treatment of patients with MGUS.

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment and ultimately a cure for multiple myeloma and other blood cancers. Drs. Berenson, Kyle and the IMBCR research team have been published in most major oncology journals such as the New England Journal of Medicine, Mayo Clinic Proceedings, BLOOD, Journal of Clinical Oncology, Science, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Nature, Oncogene and the British Journal of Haematology.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

James R. Berenson, MD

SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: